Ownership
Private
Employees
~50
Therapeutic Areas
Women's HealthOtherDermatology
Stage
Commercial
Modalities
Mesenchymal stem cell therapy

Stemform General Information

Clinical trial demonstrated 80.2% fat graft retention with ASC-enriched grafts vs 45.1% in controls for breast augmentation. Treatment showed significant improvement in clinical outcomes with no serious adverse events.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Copenhagen,
Denmark

Drug Pipeline

Stemform BA
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Stemform's pipeline data

Book a demo

Key Partnerships

Aleris Hamlet Hospitals

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Stemform Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Stemform's complete valuation and funding history, request access »